

Hadrontherapy

reimbursement procedure indication – evidence

NIHDI- Belgium



- Patients treated abroad → European hadrontherapy centers
- Scientific Committee:
 - Inclusion/exclusion criteria for proton / carbon ion therapy ("standard indications")
- Agreement Council:
 - Evaluation of individual reimbursement requests
 - Application inclusion/exclusion criteria
- → ParTICLe : protontherapy center under construction
 - \rightarrow consortium Kuleuven/UCL (University of Leuven)
 - \rightarrow collaboration UZGent/UZA/UZBrussel/CHU UCL Namur



Indications – Children (< 20 years)

NIHDI

Protontherapy - Type of tumour:

(Para)spinal, skull base chordoma Skull base chondrosarcoma (Para)spinal 'adult soft tissue' sarcoma Pelvic sarcoma Rhabdomyosarcoma Ewing's sarcoma Retinoblastoma Low-grade glioma (including optic pathway glioma) Ependymoma Craniopharyngeoma Pineal parenchymal tumours (not pineoblastoma) Esthesioneuroblastoma Medulloblastoma / primitive neuroectodermal tumours (PNET) Central nervous system germ cell tumour Non-resectable osteosarcoma



Indications – Adults

Protontherapy - Type of tumour:

Ocular melanoma (brachytherapy not possible) Paraspinal, sacral, skull base chordoma Paraspinal, sacral, skull base chondrosarcoma/sarcoma Meningioma (no other treatment available) Cerebral arterio-venous malformations (no other treatment available) Medulloblastoma

Carbon ion therapy - Type of tumour:

Malignant mucosal melanoma

Non-resectable or insufficiently resected adenoid cystic carcinoma Non-resectable or insufficiently resected salivary gland carcinoma (except for squamous cell carcinoma) Paraspinal, sacral, skull base chordoma Paraspinal, sacral, skull base chondrosarcoma/sarcoma



Additional criteria

- Cancer → Multidisciplinary Oncology Consultation :
 - Hadrontherapy is the most appropriate treatment
 - Curative intent
- "Benign" tumours of the central nervous system→ Multidisciplinary Consultation:
 - no other treatment available
 - Curative intent
- **Performance status**: grade 0 or 1, WHO classification
- **Co-morbidity?** Life expectancy > 5 yrs
- **Re-irradiation ?** only carbon ion radiation therapy



Referral procedure

1. Referral by Belgian radiotherapy centre:

 \rightarrow Belgian hospitals having signed an agreement with NIHDI

2. Request to NIHDI to obtain financing of treatment abroad

 \rightarrow application form (indication, MOC report...)

 \rightarrow consent of Hadrontherapy Centre to treat

3. Agreement Council NIHDI:

- \rightarrow case by case evaluation (inclusion/exclusion criteria)
- \rightarrow advice within 5 working days

4. Positive advice: Payment guarantee issued by NIHDI



Available evidence

- 1. Many publications (often small series, non comparative, lack of long term follow up studies...)
- 2. Expert opinion
- 3. (Randomised) clinical trails ongoing
- 4. Systematic reviews
 - KCE report: "update scientific evidence for 15 paediatric cancers" <u>https://www.ncbi.nlm.nih.gov/pubmed/27084646</u>
 - L Boltzman Institute (Austria): report Carbon Ion therapy http://eprints.hta.lbg.ac.at/1174/

- NISSS report proton therapy (Canada) https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/ Oncologie/INESSS_Protontherapie.pdf)



Available evidence

General conclusions / recommendations

→many indications: "At present insufficient or no scientific evidence to support or to refute PTB , CIRT "

→long term follow up studies needed: side effects / clinical efficacy / harms...

 \rightarrow (European) registries

 \rightarrow cost – effectiveness ?